<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6167">
  <stage>Registered</stage>
  <submitdate>21/09/2016</submitdate>
  <approvaldate>21/09/2016</approvaldate>
  <nctid>NCT02913313</nctid>
  <trial_identification>
    <studytitle>An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread</studytitle>
    <scientifictitle>Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002263-34</secondaryid>
    <secondaryid>CA020-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Broad Solid Tumor</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986207
Other interventions - Nivolumab

Experimental: Part 1A- Dose Escalation- Monotherapy - Specified dose on specified days

Experimental: Part 1B- Dose Escalation- Combination Therapy - Specified dose on specified days

Experimental: Part 2A- Expansion- Monotherapy - Specified dose on specified days

Experimental: Part 2B- Expansion- Combination Therapy - Specified dose on specified days


Treatment: drugs: BMS-986207


Other interventions: Nivolumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of adverse events of nivolumab (BMS-936558) and BMS-986207 when given in combination</outcome>
      <timepoint>Up to 15 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of clinically significant abnormalities in general laboratory tests of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of clinically significant abnormalities in general laboratory tests of nivolumab(BMS-936558) and BMS-986207 when given in combination</outcome>
      <timepoint>Up to 15 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Best Overall Response (BOR)</outcome>
      <timepoint>Up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR)</outcome>
      <timepoint>Up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>median Duration of Response (mDOR)</outcome>
      <timepoint>Up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival Rate (PFSR)</outcome>
      <timepoint>Up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed plasma concentration (Cmax) of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of maximum observed plasma concentration (Tmax) of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough observed plasma concentration (Ctrough) of BMS-986207 - Includes pre-dose concentrations [C0] and Ctau</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in one dosing interval [AUC(tau)] of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total body clearance (CLT) of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Observed concentration at the end of a dosing interval (Ctau) of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effective elimination half-life (T-HALFeff) of BMS-986207 - explains degree of accumulation observed for a specific exposure measure [exposure measure includes AUC(tau)] derived from serum concentration versus time data</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Accumulation Index (AI) of BMS-986207 - Ratio of exposure measure at steady state to that after the first dose (exposure measure includes AUC[tau]) derived from serum concentration versus time data).</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Average concentration of BMS-986207 over a dosing interval - Css-avg= AUC[TAU]/tau</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207 in combination with nivolumab (BMS-936558)</outcome>
      <timepoint>Up to 15 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor infiltrating lymphocyte (TIL) evaluations for BMS-986207 - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum cytokines profiling for BMS-986207 - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum proteome analysis for BMS-986207 - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207 - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor-specific immune cells for BMS-986207 - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor infiltrating lymphocyte (TIL) evaluations for BMS-986207 in combination with nivolumab (BMS-936558) - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum cytokines profiling for BMS-986207 in combination with nivolumab (BMS-936558) - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum proteome analysis for BMS-986207 in combination with nivolumab(BMS-936558) - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207 in combination with nivolumab (BMS-936558) - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor-specific immune cells for BMS-986207 in combination with nivolumab(BMS-936558) - This is how the pharmacodynamic activity will be measured</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Women and men =18 years of age with Eastern Cooperative Oncology Group (ECOG)
             performance status of 0 or 1

          -  Must have received and progressed on or failed one standard/approved treatment for
             cancer type, if available

          -  At least 4 weeks since any previous treatment for cancer

          -  Subject must consent to pretreatment and on treatment tumor biopsies

          -  At least one lesion with measurable disease at baseline

          -  Adequate organ and marrow function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with primary brain tumors or primary tumors with central nervous system
             metastases as only location of disease. Controlled brain metastases are permitted

          -  Prior organ transplant

          -  Participants with second/other active cancers requiring current treatment

          -  Uncontrolled/significant heart disease

          -  History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or
             Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency
             Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)

          -  Active/uncontrolled autoimmune disease

          -  Active infection

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>29/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>170</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>2/07/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Local Institution - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Ono Pharmaceutical Co. Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and effectiveness of experimental
      medication BMS-986207 by itself and in combination with Nivolumab in solid cancers that are
      advanced or have spread.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02913313</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</name>
      <address />
      <phone />
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>